|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moss EG: MicroRNAs: Hidden in the genome.
Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F,
Bao G, Kong H, Ge C, Zhang F, et al: miRNA-200c inhibits invasion
and metastasis of human non-small cell lung cancer by directly
targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu
J, Xue J, Liu T, Liang Y and Wu G: MiR-200c increases the
radiosensitivity of non-small-cell lung cancer cell line A549 by
targeting VEGF-VEGFR2 pathway. PLoS One. 8:e783442013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang C, Ding M, Xia M, Chen S, Van Le A,
Soto-Gil R, Shen Y, Wang N, Wang J, Gu W, et al: A five-miRNA panel
identified from a multicentric case-control study serves as a novel
diagnostic tool for ethnically diverse non-small-cell lung cancer
patients. EBioMedicine. 2:1377–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong CM, Wei L, Au SL, Fan DN, Zhou Y,
Tsang FH, Law CT, Lee JM, He X, Shi J, et al: MiR-200b/200c/429
subfamily negatively regulates Rho/ROCK signaling pathway to
suppress hepatocellular carcinoma metastasis. Oncotarget.
6:13658–13670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons
DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, et
al: miR-200 Inhibits lung adenocarcinoma cell invasion and
metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011.
View Article : Google Scholar :
|
|
15
|
Kim JS, Kurie JM and Ahn YH: BMP4
depletion by miR-200 inhibits tumorigenesis and metastasis of lung
adenocarcinoma cells. Mol Cancer. 14:1732015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao YF, Han ML, Xiong YJ, Wang L, Fei Y,
Shen X, Zhu Y and Liang ZQ: A micRNA-200c/cathepsin L feedback loop
determines paclitaxel resistance in human lung cancer A549 cells in
vitro through regulating epithelial-mesenchymal transition. Acta
Pharmacol Sin. 39:1034–1047. 2018. View Article : Google Scholar
|
|
17
|
Nishijima N, Seike M, Soeno C, Chiba M,
Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A:
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small
cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu M, Bi F, Zhou X and Zheng Y: Rho
GTPase regulation by miRNAs and covalent modifications. Trends Cell
Biol. 22:365–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wennerberg K, Forget MA, Ellerbroek SM,
Arthur WT, Burridge K, Settleman J, Der CJ and Hansen SH: Rnd
proteins function as RhoA antagonists by activating p190 RhoGAP.
Curr Biol. 13:1106–1115. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ongusaha PP, Kim HG, Boswell SA, Ridley
AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA and Lee SW: RhoE is a
pro-survival p53 target gene that inhibits ROCK I-mediated
apoptosis in response to genotoxic stress. Curr Biol. 16:2466–2472.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu Y, Zhou J, Xia H, Chen X, Qiu M, Huang
J, Liu S, Tang Q, Lang N, Liu Z, et al: The Rho GTPase RhoE is a
p53-regulated candidate tumor suppressor in cancer cells. Int J
Oncol. 44:896–904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang C, Zhou F, Li N, Shi S, Feng X, Chen
Z, Hang J, Qiu B, Li B, Chang S, et al: Overexpression of RhoE has
a prognostic value in non-small cell lung cancer. Ann Surg Oncol.
14:2628–2635. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cuiyan Z, Jie H, Fang Z, Kezhi Z, Junting
W, Susheng S, Xiaoli F, Ning L, Xinhua M, Zhaoli C, et al:
Overexpression of RhoE in non-small cell lung cancer (NSCLC) is
associated with smoking and correlates with DNA copy number
changes. Cancer Biol Ther. 6:335–342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
25
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M,
et al: Combinatorial microRNA target predictions. Nat Genet.
37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bektic J, Pfeil K, Berger AP, Ramoner R,
Pelzer A, Schäfer G, Kofler K, Bartsch G and Klocker H: Small
G-protein RhoE is underexpressed in prostate cancer and induces
cell cycle arrest and apoptosis. Prostate. 64:332–340. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q,
Chen J, Chen X, Zhang S, Liu Z, et al: miR-137 targets Cdc42
expression, induces cell cycle G1 arrest and inhibits invasion in
colorectal cancer cells. Int J Cancer. 128:1269–1279. 2011.
View Article : Google Scholar
|
|
28
|
Feng X, Wang Z, Fillmore R and Xi Y:
MiR-200, a new star miRNA in human cancer. Cancer Lett.
344:166–173. 2014. View Article : Google Scholar :
|
|
29
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop - a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vallejo DM, Caparros E and Dominguez M:
Targeting Notch signalling by the conserved miR-8/200 microRNA
family in development and cancer cells. EMBO J. 30:756–769. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar
|
|
33
|
Yu J, Ohuchida K, Mizumoto K, Sato N,
Kayashima T, Fujita H, Nakata K and Tanaka M: MicroRNA,
hsa-miR-200c, is an independent prognostic factor in pancreatic
cancer and its upregulation inhibits pancreatic cancer invasion but
increases cell proliferation. Mol Cancer. 9:1692010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sato H, Shien K, Tomida S, Okayasu K,
Suzawa K, Hashida S, Torigoe H, Watanabe M, Yamamoto H, Soh J, et
al: Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI
resistance non-small cell lung cancer cells harboring EMT features.
Sci Rep. 7:408472017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shimono Y, Zabala M, Cho RW, Lobo N,
Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ,
Hwang SY, Kim WY, Kim TJ, Lee JH, Kim BG, et al: Altered MicroRNA
expression in cervical carcinomas. Clin Cancer Res. 14:2535–2542.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang L, Deng T, Li X, Liu H, Zhou H, Ma
J, Wu M, Zhou M, Shen S, Li X, et al: microRNA-141 is involved in a
nasopha-ryngeal carcinoma-related genes network. Carcinogenesis.
31:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nobes CD, Lauritzen I, Mattei MG, Paris S,
Hall A and Chardin P: A new member of the Rho family, Rnd1,
promotes disassembly of actin filament structures and loss of cell
adhesion. J Cell Biol. 141:187–197. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Foster R, Hu KQ, Lu Y, Nolan KM, Thissen J
and Settleman J: Identification of a novel human Rho protein with
unusual properties: GTPase deficiency and in vivo farnesylation.
Mol Cell Biol. 16:2689–2699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Riou P, Villalonga P and Ridley AJ: Rnd
proteins: Multifunctional regulators of the cytoskeleton and cell
cycle progression. BioEssays. 32:986–992. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Raz DJ, Ray MR, Kim JY, He B, Taron M,
Skrzypski M, Segal M, Gandara DR, Rosell R and Jablons DM: A
multigene assay is prognostic of survival in patients with
early-stage lung adenocarcinoma. Clin Cancer Res. 14:5565–5570.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Paysan L, Piquet L, Saltel F and Moreau V:
Rnd3 in cancer: A Review of the evidence for tumor promoter or
suppressor. Mol Cancer Res. 14:1033–1044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang Y, Hu C, Yang H, Cao L, Li Y, Deng P
and Huang L: Rnd3 regulates lung cancer cell proliferation through
notch signaling. PLoS One. 9:e1118972014. View Article : Google Scholar : PubMed/NCBI
|
